Five-day treatment of non-severe, community-acquired pneumonia with josamycin.
This study assessed the efficacy of oral josamycin 1 g bd for five days as treatment for non-severe, community-acquired pneumonia in patients less than 60 years of age who were not at obvious risk of developing respiratory tract infection caused by aerobic Gram-negative bacilli. Of the 84 patients (43 male, 41 female) with a mean age of 33 years who were enrolled during a 14-month period, the clinical outcome was invariably favourable. All patients became afebrile within three days of starting therapy; the mean duration of fever after initiating treatment was 1.7 days. Therefore, according to the study protocol, josamycin therapy was discontinued on day five. A chest X-ray performed four to six weeks after completing treatment was normal in every case and no relapses were observed during a six-week follow-up period. We conclude that a five-day course of josamycin is effective monotherapy for community-acquired pneumonia in patients without the clinical features of severe infection.
Mensa
J
J
Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain.
Trilla
A
A
Moreno
A
A
Vidal
J
J
Espaulella
J
J
Soriano
E
E
Garcia San Miguel
J
J
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015570:Josamycin / Q000627:therapeutic use*; D007877:Legionnaires' Disease / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy / Q000382:microbiology; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy / Q000382:microbiology; D011778:Q Fever / Q000188:drug therapy / Q000382:microbiology; D012008:Recurrence
D015570:Josamycin